SS Innovations International (NASDAQ: SSII) has supported the launch of Sri Lanka's first robotic cardiac surgery program at Kings Hospital Colombo, using the SSi Mantra 3.0 surgical robotic system. The program commenced with a robotic-assisted left internal mammary artery (LIMA) takedown, performed by Dr. Sudhir Srivastava, founder and chairman of SS Innovations, alongside Kings Hospital cardiothoracic surgeon Dr. Rajitha DeSilva. This development, highlighted in a recent company video, signifies a major advancement in Sri Lanka's healthcare capabilities and underscores the growing adoption of robotic surgery in emerging markets.
The introduction of robotic cardiac surgery in Sri Lanka is important because it brings advanced, minimally invasive options to patients who previously had limited access to such technology. Robotic-assisted cardiac procedures can offer benefits such as smaller incisions, reduced pain, shorter hospital stays, and faster recovery compared to traditional open-heart surgery. By establishing this program, Kings Hospital Colombo becomes a pioneer in the region, potentially attracting patients from across South Asia and elevating the standard of cardiac care. According to the company video, Kings Hospital has already completed more than 25 robotic procedures in just three weeks, demonstrating rapid adoption and proficiency with the SSi Mantra system.
For SS Innovations, this launch represents a strategic milestone in its global expansion. The company reported 224 cumulative SSi Mantra installations across 12 countries at the end of the second quarter, indicating a growing international presence. The second-quarter revenue reached $13.9 million, while robotic procedures increased 143% year over year to 2,528, pointing to rising utilization of the company's installed base. These figures suggest that SS Innovations is not only selling systems but also seeing increased use, which is crucial for long-term recurring revenue and market validation. The successful deployment in Sri Lanka adds to the company's credibility and showcases the versatility of the SSi Mantra 3.0 in complex cardiac procedures.
Looking ahead, SS Innovations is pursuing U.S. FDA clearance and European CE marking for the SSi Mantra system. These regulatory milestones are critical for entering major markets and competing with established players in the surgical robotics industry. Achieving FDA clearance would allow SS Innovations to tap into the largest healthcare market globally, while CE marking would open doors across Europe. The Sri Lanka program serves as a proof point for the system's clinical efficacy and safety, which could support regulatory submissions. As the company continues to expand its footprint, successful outcomes in diverse settings like Sri Lanka will be instrumental in building trust among surgeons, hospitals, and regulators.
The launch also has implications for the broader adoption of robotic surgery in developing countries. It demonstrates that advanced surgical technologies can be effectively implemented in resource-constrained environments, potentially inspiring other hospitals in the region to follow suit. For patients in Sri Lanka, this means access to world-class surgical care without the need to travel abroad. For SS Innovations, it reinforces its mission to democratize robotic surgery and positions the company as a key player in the global shift toward minimally invasive procedures. As the program grows, it could serve as a training hub for surgeons across South Asia, further accelerating the adoption of robotic cardiac surgery.
In summary, SS Innovations' support of Sri Lanka's first robotic cardiac surgery program is a significant development that benefits patients, enhances the company's global standing, and paves the way for regulatory approvals in the U.S. and Europe. The early success at Kings Hospital Colombo highlights the potential of the SSi Mantra system and signals a new era in cardiac care for the region.
